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Precision medicine for suicidality: from universality to
subtypes and personalization
AB Niculescu1,2,3,4, H Le-Niculescu1,8, DF Levey1,2,8, PL Phalen3,8, HL Dainton1, K Roseberry1, EM Niculescu1, JO Niezer1, A Williams3,
DL Graham3, TJ Jones3, V Venugopal1, A Ballew5, M Yard4, T Gelbart6, SM Kurian6, A Shekhar1, NJ Schork7, GE Sandusky4 and
DR Salomon6,†
Suicide remains a clear, present and increasing public health problem, despite being a potentially preventable tragedy. Its incidence
is particularly high in people with overt or un(der)diagnosed psychiatric disorders. Objective and precise identiﬁcation of individuals
at risk, ways of monitoring response to treatments and novel preventive therapeutics need to be discovered, employed and widely
deployed. We sought to investigate whether blood gene expression biomarkers for suicide (that is, a ‘liquid biopsy’ approach) can
be identiﬁed that are more universal in nature, working across psychiatric diagnoses and genders, using larger cohorts than in
previous studies. Such markers may reﬂect and/or be a proxy for the core biology of suicide. We were successful in this endeavor,
using a comprehensive stepwise approach, leading to a wealth of ﬁndings. Steps 1, 2 and 3 were discovery, prioritization and
validation for tracking suicidality, resulting in a Top Dozen list of candidate biomarkers comprising the top biomarkers from each
step, as well as a larger list of 148 candidate biomarkers that survived Bonferroni correction in the validation step. Step 4 was
testing the Top Dozen list and Bonferroni biomarker list for predictive ability for suicidal ideation (SI) and for future hospitalizations
for suicidality in independent cohorts, leading to the identiﬁcation of completely novel predictive biomarkers (such as CLN5 and
AK2), as well as reinforcement of ours and others previous ﬁndings in the ﬁeld (such as SLC4A4 and SKA2). Additionally, we
examined whether subtypes of suicidality can be identiﬁed based on mental state at the time of high SI and identiﬁed four
potential subtypes: high anxiety, low mood, combined and non-affective (psychotic). Such subtypes may delineate groups of
individuals that are more homogenous in terms of suicidality biology and behavior. We also studied a more personalized approach,
by psychiatric diagnosis and gender, with a focus on bipolar males, the highest risk group. Such a personalized approach may be
more sensitive to gender differences and to the impact of psychiatric co-morbidities and medications. We compared testing the
universal biomarkers in everybody versus testing by subtypes versus personalized by gender and diagnosis, and show that the
subtype and personalized approaches permit enhanced precision of predictions for different universal biomarkers. In particular,
LHFP appears to be a strong predictor for suicidality in males with depression. We also directly examined whether biomarkers
discovered using male bipolars only are better predictors in a male bipolar independent cohort than universal biomarkers and show
evidence for a possible advantage of personalization. We identiﬁed completely novel biomarkers (such as SPTBN1 and C7orf73),
and reinforced previously known biomarkers (such as PTEN and SAT1). For diagnostic ability testing purposes, we also examined as
predictors phenotypic measures as apps (for suicide risk (CFI-S, Convergent Functional Information for Suicidality) and for anxiety
and mood (SASS, Simpliﬁed Affective State Scale)) by themselves, as well as in combination with the top biomarkers (the
combination being our a priori primary endpoint), to provide context and enhance precision of predictions. We obtained area
under the curves of 90% for SI and 77% for future hospitalizations in independent cohorts. Step 5 was to look for mechanistic
understanding, starting with examining evidence for the Top Dozen and Bonferroni biomarkers for involvement in other psychiatric
and non-psychiatric disorders, as a mechanism for biological predisposition and vulnerability. The biomarkers we identiﬁed also
provide a window towards understanding the biology of suicide, implicating biological pathways related to neurogenesis,
programmed cell death and insulin signaling from the universal biomarkers, as well as mTOR signaling from the male bipolar
biomarkers. In particular, HTR2A increase coupled with ARRB1 and GSK3B decreases in expression in suicidality may provide a
synergistic mechanistical corrective target, as do SLC4A4 increase coupled with AHCYL1 and AHCYL2 decrease. Step 6 was to move
beyond diagnostics and mechanistical risk assessment, towards providing a foundation for personalized therapeutics. Items scored
positive in the CFI-S and subtypes identiﬁed by SASS in different individuals provide targets for personalized (psycho)therapy. Some
individual biomarkers are targets of existing drugs used to treat mood disorders and suicidality (lithium, clozapine and omega-3
fatty acids), providing a means toward pharmacogenomics stratiﬁcation of patients and monitoring of response to treatment. Such
biomarkers merit evaluation in clinical trials. Bioinformatics drug repurposing analyses with the gene expression biosignatures of
the Top Dozen and Bonferroni-validated universal biomarkers identiﬁed novel potential therapeutics for suicidality, such as ebselen
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(a lithium mimetic), piracetam (a nootropic), chlorogenic acid (a polyphenol) and metformin (an antidiabetic and possible longevity
promoting drug). Finally, based on the totality of our data and of the evidence in the ﬁeld to date, a convergent functional evidence
score prioritizing biomarkers that have all around evidence (track suicidality, predict it, are reﬂective of biological predisposition and
are potential drug targets) brought to the fore APOE and IL6 from among the universal biomarkers, suggesting an inﬂammatory/
accelerated aging component that may be a targetable common denominator.
Molecular Psychiatry (2017) 22, 1250–1273; doi:10.1038/mp.2017.128; published online 1 August 2017
INTRODUCTION
‘Individuality in universality is the plan of creation’.
-Swami Vivekananda
Objective and quantitative markers would permit better and
more precise assessment, tracking and prediction of suicidal risk,
which would enable preventive therapeutic interventions.1–3
Previous work by our group has identiﬁed blood biomarkers and
phenotypic predictors for suicide risk in men4 and separately in
women,5 showing some gender similarities as well as differences.
An essential question remained to be answered, of high relevance
for developing this area of research and carrying it to full clinical
applicability: would a quest for more universal predictors or a
quest for more personalized predictors be more productive? We
endeavored to answer this question through our current work.
First, we sought to investigate whether blood gene expression
biomarkers can be identiﬁed that are more universal in nature,
working across psychiatric diagnoses and genders, starting with a
powerful longitudinal within-participant6 design and using larger
cohorts than in previous studies7,4,5 (Figure 1). Second, we
identiﬁed subtypes of suicidality based on mental state (anxiety,
mood and psychosis) at the time of high suicidal ideation.8–10
Third, we used a more personalized approach, by gender and
diagnosis, with a focus on the highest clinical risk group, male
bipolars. We examined the ability of the universal candidate
biomarkers to predict suicidal ideation (SI) and future hospitaliza-
tions for suicidality, in completely independent cohorts, in
everybody, as well as divided by subtypes, and personalized by
gender and diagnosis. We also directly compared the universal
biomarkers with biomarkers discovered using male bipolars only,
for ability to predict SI and future hospitalizations for suicidality in
independent cohorts of male bipolars.
Per our a priori design described in previous studies,4,5 we also
combined the top biomarkers with scores obtained with a clinical
information measure of suicide risk (Convergent Functional
Information for Suicidality, CFI-S), as well as with scores for
anxiety and mood obtained with an 11-item visual analog scale
(Simpliﬁed Affective State Scale, SASS),4,5,8 to obtain a broader
spectrum predictor (UP-Suicide) that puts the biomarkers in the
context of the person’s life and his/hers mental state. The triggers
for suicide may be the individual’s perceptions of being
unsuccessful, with no future, suffering, damaged, along with
mental frailty, addictions and cultural exposure to suicide. Our CFI-
S scale captures such information about who a person is, and
along with the SASS scale that captures mental state information
and permits classiﬁcation in subtypes, they add a broader context
to the objective blood biomarker predictors we have uncovered
(Figure 5). Of note, these scales do not ask about SI, as individuals
who want to commit suicide may not always share that
information, for fear of being stopped.
We also used the lists of top biomarkers we identiﬁed as a
window into the biology of suicidality, by conducting biological
pathways and network analyses, and by looking at co-morbidity
with other disorders that may predispose or create a vulnerability
to suicidality.
In addition, we leveraged these lists for therapeutics and drug
discovery purposes, to see whether some of the biomarkers we
identiﬁed are modulated by existing compounds used to treat
suicidality and also to conduct bioinformatics drug repurposing
analyses to discover new drugs and natural compounds that may
be useful for treating suicidality.
Finally, we integrated the totality of evidence we have gene-
rated in this study and available in the literature to date, to
prioritize biomarkers for future clinical studies in the ﬁeld.
MATERIALS AND METHODS
Cohorts
We used three independent cohorts: discovery (a live psychiatric
participants cohort), validation (a postmortem coroner’s ofﬁce
suicide completers cohort) and testing (an independent live
psychiatric participants test cohort for predicting SI and for
predicting future hospitalizations for suicidality) (Figure 1a).
Similar to our previous studies,7,4,5 the live psychiatric partici-
pants are part of a larger longitudinal cohort of adults that we are
continuously collecting. Participants are recruited from the patient
population at the Indianapolis VA Medical Center and Indiana
University School of Medicine. All participants understood and
signed informed consent forms detailing the research goals,
procedure, caveats and safeguards, per Institutional Review Board-
approved protocol. Participants completed diagnostic assess-
ments by an extensive structured clinical interview—Diagnostic
Interview for Genetic Studies—at a baseline visit, followed by up
to six testing visits, 3–6 months apart or whenever a new
psychiatric hospitalization occurred. At each testing visit, they
received a series of psychiatric rating scales, including the
Hamilton Rating Scale for Depression-17, which includes a SI
rating item (Supplementary Figure S1), and their blood was drawn.
We collected whole blood (10 ml) in two RNA-stabilizing PAXgene
tubes, labeled with an anonymized ID number and stored at − 80 °
C in a locked freezer until the time of future processing. Whole-
blood RNA was extracted for microarray gene expression studies
from the PAXgene tubes, as detailed below.
For this study, our within-participant discovery cohort, from
which the biomarker data were derived, consisted of 66 partici-
pants (49 males and 17 females) with psychiatric disorders and
multiple testing visits, who each had at least one diametric change
in SI scores from no SI to high SI, or vice versa, from one testing
visit to another. There were 2 participants with 6 visits each, 3
participants with 5 visits each, 5 participants with 4 visits each, 34
participants with 3 visits each and 22 participants with 2 visits
each, resulting in a total of 193 blood samples for subsequent
gene expression microarray studies (Figure 1 and Table 1 and S1).
Our postmortem cohort, in which the top biomarker ﬁndings
were validated for behavior, consisted of 38 male and 7 female
violent suicide completers obtained through the Marion County
coroner’s ofﬁce (Table 1). We required a last observed alive
postmortem interval of 24 h or less and the cases selected had to
have completed suicide by means other than overdose, which
could affect gene expression. Thirty-one participants completed
suicide by gunshot to head or chest, 12 by asphyxiation, 1 by slit
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wrist and 1 by electrocution. Next of kin signed informed consent
at the coroner’s ofﬁce for donation of blood for research.
Our independent test cohort for predicting SI (Table 1)
consisted of 184 male and 42 female participants with psychiatric
disorders, demographically matched with the discovery cohort,
with one or multiple testing visits in our lab, with either no SI,
intermediate SI or high SI, resulting in a total of 226 blood samples
in which whole-genome blood gene expression data were
obtained (Figure 1 and Table 1 and S1).
Our test cohort for predicting future hospitalizations (Figure 1
and Table 1 and S1) is a subset (170 males and 24 females) of the
independent test cohort for which we had longitudinal follow-up
with electronic medical records. The participants’ subsequent
number of psychiatric hospitalizations, with or without suicidality
(ideation or attempt), was tabulated from electronic medical
records. Participants were evaluated for the presence of future
hospitalizations for suicidality and for the frequency of such
hospitalizations. A hospitalization was deemed to be without
suicidality if suicidality was not listed as a reason for admission
and no SI was described in the admission and discharge medical
notes. Conversely, a hospitalization was deemed to be due to
suicidality if suicidal acts or intent were listed as a reason for
admission and/or SI was described in the admission and discharge
medical notes.
Complete Materials and Methods are available in the
Supplementary Information. Of note, all genomic and phenomic
data was normalized (z-scored) by gender and psychiatric
diagnosis before being combined and analyzed.
Figure 1. Steps 1–3: discovery, prioritization and validation. (a) Cohorts used in study, depicting ﬂow of discovery, prioritization and validation
of biomarkers from each step. (b) Discovery cohort longitudinal within-participant analysis. Phchp### is study ID for each participant. V#
denotes visit number (1, 2, 3, 4, 5 or 6). (c) Discovery of possible subtypes of suicidality based on high suicidal ideation (SI) visits in the
discovery cohort. Participants were clustered using measures of mood and anxiety (Simpliﬁed Affective State Scale (SASS)), as well as
psychosis (PANSS Positive) (d) Differential gene expression in the Discovery cohort, number of genes identiﬁed with DE and AP methods with
an internal score of 1 and above. Red, increased in expression in high SI. Blue, decreased in expression in high SI. At the discovery step
probesets are identiﬁed based on their score for tracking SI with a maximum of internal points of 4 (33% (1 pt), 50% (2 pt) and 80% (4 pt)). (e)
Prioritization with Convergent Functional Genomics (CFG) for prior evidence of involvement in suicide. In the prioritization step probesets are
converted to their associated genes using Affymetrix annotation and GeneCards. Genes are prioritized and scored using CFG for Suicide
evidence with a maximum of eight external points. Genes scoring at least 4 points out of a maximum possible of 12 points total internal and
external score are carried to the validation step. (f) Validation in an independent suicide completers cohort from the coroner’s ofﬁce. In the
validation step biomarkers are assessed for stepwise change from the discovery groups of participants with no SI, to high SI, to suicide
completion, using analysis of variance. Stringent Bonferroni correction is calculated for the total number of probesets analyzed.
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Table 1. Demographics
A. Universal Participants Gender Diagnosis Ethnicity Age mean (s.d.)
Discovery
Discovery cohort (longitudinal within-participant changes in SI) 66 Male= 49
Female= 17
BP= 25
MDD= 17
SZA= 9
SZ= 4
PTSD= 8
MOOD= 2
PSYCH= 1
EA= 51
AA= 14
Asian= 1
47.94
(9.47)
Validation
Independent validation cohort for gene expression (suicide completers) 45 Male= 38
Female= 7
NP= 19
MDD= 19
BP= 2
SZ= 1
AX= 1
Alcoholism= 1
ADHD= 1
PTSD= 1
EA= 37
AA= 7
Hispanic= 1
40.69
(16.93)
Testing
All
Independent testing cohort for predicting state (SI at time of assessment) 226 Male= 184
Female= 42
BP= 68
MDD= 32
SZA= 53
SZ= 45
PTSD= 19
MOOD= 5
PSYCH= 4
EA= 148
AA= 73
Asian= 1
Hispanic= 3
Mixed= 1
All= 50.26
(9.47)
No SI= 51.1
Intermediate SI= 49
High SI= 44.3
Independent testing cohort for predicting trait (hospitalizations for suicidality in the
year following assessment)
194 Male= 170
Female= 24
BP= 52
MDD= 30
SZA= 45
SZ= 43
PTSD= 16
MOOD= 5
PSYCH= 3
EA= 126
AA= 64
Hispanic= 3
Mixed= 1
All= 50.65 (9.14)
No Hosp for SI= 50.91
Hosp for SI= 47.66
Subtypes
High anxiety subtype 46 Male= 40
Female= 6
BP= 13
MDD= 10
SZA= 9
SZ= 11
PTSD= 2
MOOD= 1
EA= 27
AA= 19
All= 50.96
(7.63)
No SI= 52.1
Intermediate SI= 52.5
High SI= 39.4
Low mood subtype 76 Male= 57
Female= 19
BP= 21
MDD= 17
SZA= 15
SZ= 15
PTSD= 6
MOOD= 1
PSYCH= 1
EA= 53
AA= 20
Hispanic= 2
Asian= 1
All= 51.53
(10.04)
No SI= 51.44
Intermediate SI= 51.81
High SI= 51.9
Combined subtype 86 Male= 61
Female= 25
BP= 30
MDD= 11
SZA= 21
SZ= 11
PTSD= 11
MOOD= 2
EA= 63
AA= 21
Hispanic= 1
Mixed= 1
All= 47.95
(9.36)
No SI= 50.79
Intermediate SI= 45.43
High SI= 43.06
Non-affective (psychotic) subtype 141 Male= 121
Female= 20
BP= 40
MDD= 17
SZA= 35
SZ= 32
PTSD= 10
MOOD= 4
PSYCH= 3
EA= 86
AA= 52
Hispanic= 2
Mixed= 1
All= 50.71
(9.49)
No SI= 50.89
Intermediate SI= 51.67
High SI= 42.33
B. Male bipolar Participants Gender Diagnosis Ethnicity Age mean (s.d.)
Discovery
Male bipolar discovery cohort (within-participant changes in SI) 20 Male= 20 BP= 20 EA= 20 48.12
(9.10)
Validation
Male independent validation cohort for gene expression (suicide completers) 38 Male= 38 NP= 18
MDD= 16
BP= 1
SZ= 1
AX= 1
Alcoholism= 1
EA= 31
AA= 6
Hispanic= 1
40.82
(17.31)
Testing
Male bipolar independent testing cohort for predicting state (SI at time of assessment) 49 Male= 49 BP= 49 EA= 43
AA= 5
Hispanic= 1
All= 49.16
(10.01)
No SI= 50.19
Intermediate SI= 48.73
High SI= 40.42
Male bipolar independent testing cohort for predicting trait (hospitalizations for
suicidality in the year following assessment)
44 Male= 44 BP= 44 EA= 39
AA= 4
Hispanic= 1
All= 48.88
(10.23)
No Hosp for SI= 48.76
Hosp for SI= 52.25
Abbreviations: AA, African Amercian; ADHD, attention deﬁcit disorder; AX, anxiety disorder; BP, bipolar; EA, European-American; MDD, major depressive
disorder; MOOD, mood disorder not otherwise speciﬁed; NP, non-psychiatric; PSYCH, psychosis not otherwise speciﬁed; PTSD, post-traumatic stress disorder;
SZA, schizoaffective disorder; SZ, schizophrenia.
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RESULTS
Step 1: Discovery
We used a powerful within-participant longitudinal discovery
approach to identify genes that: (1) change in expression in blood
between no SI and high SI states; (2) track the SI state across visits in
a participant; and (3) track the SI state in multiple participants. We
used a longitudinally followed cohort of participants that showed
diametric changes in SI between at least two testing visits (n=66
participants out of a cohort of 293 men and women psychiatric
disorder participants followed longitudinally, with diagnoses of
bipolar disorder, depression, mood disorder nos, schizophrenia,
schizoaffective disorder, psychosis nos and post-traumatic stress
disorder). Using our 33% of maximum raw score threshold (internal
score of 1 pt),4,5 we had 10 468 unique probesets from Affymetrix
Absent/Present (AP) analyses and Differential Expression (DE)
analyses (Figure 1d). These were carried forward to the prioritization
step. This represents approximately a ﬁvefold enrichment of the
54 625 probesets on the Affymetrix array.
We also examined in the discovery cohort whether subtypes of
suicidality can be identiﬁed based on mental state at the time of
high SI visits, using two-way hierarchical clustering with anxiety,
mood and psychosis measures. The SI state self-report may be
more reliable in this cohort, as the participants demonstrated the
aptitude and willingness to report different and diametric SI
states. We uncovered four potential subtypes of suicidality: high
anxiety, low mood, co-morbid and non-affective (psychotic)
(Figure 1c). These subtypes need to be tested in independent
cohorts for practical utility, diagnostic and therapeutic.
Step 2: Prioritization
We used a Convergent Functional Genomics approach to prioritize
the candidate biomarkers identiﬁed in the discovery step (internal
score of ⩾ 1 pt) by using all the published prior independent
evidence in the ﬁeld (Figure 1e). There were 583 probesets that
had a Convergent Functional Genomics score (combined internal
and external score) of 4 and above. These were carried forward to
the validation step. This represents approximately a 100-fold
enrichment of the probesets on the Affymetrix array.
Step 3: Validation
Next, we validated for suicidal behavior these prioritized biomarkers,
in a demographically matched cohort of men and women suicide
completers from the coroner’s ofﬁce (n=45), by assessing which
markers were stepwise changed in expression from no SI to high SI
to suicide completers (Figure 1). Two hundred and seventy-four
probesets were non-stepwise changed and 309 were stepwise
changed. Of these, 148 survived Bonferroni correction for all the 583
probesets validated. This represents approximately a 500-fold
enrichment of the probesets on the Affymetrix array.
Step 4: Testing for diagnostics
We tested for diagnostic ability in independent cohorts two
overlapping sets of biomarkers: the universal Top Dozen
biomarkers (composed of the top increased and decreased
biomarkers from AP and from DE from each step: discovery,
prioritization and validation) (Table 2), as well as all the universal
Bonferroni biomarkers, that survived correction for multiple
comparisons after the validation step (Supplementary Table S2).
The biomarkers were tested individually (the 12 biomarkers from
the Top Dozen list and 148 biomarkers from the Bonferroni list), as
well as in panels (BioM12 and BioM 148), in a completely
independent test cohort of men and women psychiatric disorder
participants (n= 226), for prediction of SI state, as well as for
prediction of future psychiatric hospitalizations due to suicidality
(Figures 2 and 3, Table 3 and Supplementary Table S4). We were
successful in this endeavor, leading to identiﬁcation of universal
biomarkers that work across gender and diagnoses, such as CLN5
and AK2.
We also studied their predictive ability in participants in the
independent cohort grouped by the subtypes described above, as
well as grouped by a more personalized approach, by psychiatric
diagnosis and gender. We then compared the universal approach
to the subtypes approach and the personalized approach, and
show that the subtype and personalized approaches permit
enhanced precision of predictions for different biomarkers
(Figures 2 and 3, Supplementary Figure S2, Table 3 and Supplem-
entary Table S4).
For SI prediction in the independent test cohort, CLN5, from the
Bonferroni biomarkers list, a decreased in expression biomarker,
had an area under the curve (AUC) of 65% (P= 1.86E− 04) across
all subjects, and 75% (4.43E− 03) in the low mood subtype. It also
survived correction for multiple comparisons for the Step 4 testing
of the 154 universal biomarkers (from the combined Top Dozen
and Bonferroni lists). CLN5 also had an AUC of 87% (P= 1.16E− 02)
for predicting future hospitalizations for suicidality in the ﬁrst year
of follow-up in male post-traumatic stress disorder. CLN5 (ceroid-
lipofuscinosis, neuronal 5) is a completely novel ﬁnding. It has no
prior evidence as a biomarker for suicide or for involvement in
other psychiatric disorders. CLN5 is a lysosomal regulatory protein,
known to date to be involved in neurodegenerative, lysosomal
storage diseases.
For prediction of future hospitalizations for suicidality in the ﬁrst
year of follow-up in the independent test cohort, AK2, from the
Bonferroni biomarkers list, a decreased in expression biomarker, had
an AUC of 60% (P=2.31E−02) across all subjects, 68%
(P=6.72E−03) in the combined subtype and 78% (P=2.70E− 03)
for male schizoaffectives. AK2 also had an AUC of 64%
(P=5.39E−04) for predicting SI state across all subjects in the
independent test cohort, as well as an AUC of 75% (P=2.93E− 02)
in male schizophrenia. AK2 (adenylate kinase 2) is also a completely
novel ﬁnding. It has no prior evidence as a biomarker for suicide,
but does have evidence for a decrease in expression in brains of
schizophrenics.11 AK2 is a mitochondrial gene, known to have an
important role in cellular energy homeostasis and in adenine
nucleotide metabolism, as well as may have a role in apoptosis.
As for examples of previously known biomarkers reproduced
in this study, for SI prediction in the independent test
cohort, SLC4A4, a top increased in expression biomarker, had
an AUC of 64% (P= 3.83E− 04) across all subjects, 69% (6.13E− 04)
in the combined subtype and 77% (9.72E− 04) in male
bipolars. SKA2, a top decreased in expression biomarker, had
an AUC of 61% (P= 3.35E− 03) across all subjects, 74% (5.91E− 03)
in the low mood subtype and 79% (1.35E− 02) in male
schizophrenics.
In addition, we used two previously described clinical instru-
ments in the form of apps, the SASS that measures anxiety and
mood, and the CFI-S that measures risk for suicide indirectly,
without asking about SI.4,5 The scores from these apps showed
good predictive ability for both state (SI) and trait (future
hospitalizations), in all participants (Figure 4, Table 3). There are
interesting variations in different subtypes and personalized by
gender and diagnosis (Supplementary Table S4), suggesting the
distinctness and homogeneity of those subgroups.
We also combined a panel of the Top Dozen biomarkers with
measures of anxiety and mood (SASS), and with the suicide risk
scale (CFI-S), into a broad spectrum universal predictor algorithm
(UP Suicide), our a priori endpoint as in our previous studies. The
UP Suicide provides the biomarkers with mental state (SASS) and
personal history context (CFI-S), enhancing precision of predic-
tions (Figures 5 and 6). Across all subjects in the independent test
cohort, UP Suicide 12 had an AUC of 90% (P= 3.87E− 21) for state
(SI) prediction, as well as an AUC of 77% (P= 2.87E− 08) for trait
(future hospitalizations for suicidality) predictions. The results for
predicting SI were even stronger in the low mood subtype (AUC of
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Table 2. The Top Dozen list of candidate biomarker genes - evidence for involvement in suicidality
A. Top Dozen biomarkers from universal approach
Gene symbol
Gene name
Probesets Discovery
(direction of change)
method/score
Prior human
genetic evidence
for suicide
Prior human brain
expression evidence
for suicide
Prior human peripheral
expression evidence
for suicide
Prioritization
total
CFG score for
suicide
Validation
ANOVA
P-value
Descriptor
Top biomarkers from discovery—step 1
HIST1H2BO
Histone cluster 1, H2bo
214540_at (I)
DE/4
Our previous work in males
(I)(214540_at) Blood4
4 5.37E− 14 Top discovery DE
increased gene
ERG
V-ets avian erythroblastosis virus E26 oncogene
homolog
213541_s_at (D)
DE/4
Our previous work in males (D)
(213541_s_at) Blood4
Our previous work in females (D)
(213541_s_at) Blood5
4 NS Top discovery DE
decreased gene
GAB1
GRB2-associated binding protein 1
242572_at (I)
AP/4
Our previous work in males (I)
(242572_at) Blood4
4 NS Top discovery AP
increased gene
CCL28
Chemokine (C–C motif ) ligand 28
224240_s_at (D)
AP/4
Our previous work in males (D)
(224240_s_at) Blood4
Our previous work in females (D)
(224240_s_at) Blood5
4 NS Top discovery AP
Decreased gene
Top biomarkers from prioritization—step 2
HTR2A
5-Hydroxytryptamine (serotonin) receptor 2A, G
protein-coupled
244130_at (I)
DE/2
Association28–33 (I) Prefrontal cortex34
(I) Frontal cortex35,36
(D)
Platelets37
Our previous work in females
(D)
(244130_at) Blood5
10 NS Top prioritization DE
increased gene
SKA2
Spindle and kinetochore-associated complex
subunit 2
225686_at (D)DE/1
(D)AP/1
Association38 (D) Prefrontal cortex38 (D)Blood38
(D)Blood, saliva39
Our previous work in males
(D)(225686_at) Blood4
9 0.0045542 Top prioritization DE
decreased gene
SLC4A4
Solute carrier family 4 (sodium bicarbonate
cotransporter), member 4
210739_x_at (I)
AP/1
Association40 (D) Prefrontal cortex(BA
46/10)41
Our previous work in males
(I)(210739_x_at) Blood4
7 7.74E− 05 Top prioritization AP
increased gene
IFNG
Interferon, gamma
210354_at (D)
AP/1
Association42 (D) Hippocampus43 (D) Blood44
Our previous work in females (D)
(210354_at) Blood5
9 NS Top prioritization AP
decreased gene
Top biomarkers from validation—step 3
PSME4
Proteasome activator subunit 4
237180_at (I)
DE/1
(I) Anterior cingulate
cortex20
5 2.64E− 36 Top validation DE
increased gene
LDLRAP1
Low-density lipoprotein receptor adaptor
protein 1
57082_at (D)
DE/1
(I)
Anterior cingulate
cortex20
Our previous work in males
(D)(221790_s_at) Blood4
5 1.48E− 38 Top validation DE
decreased gene
PPAP2B
Phosphatidic acid phosphatase type 2B
212226_s_at (I)AP/1 (D) Prefrontal cortex (BA
46/10)41
Our previous work in females
(I)(212226_s_at) Blood5
5 2.76E− 17 Top validation AP
increased gene
ARRB1
Arrestin, beta 1
218832_x_at (D)
AP/1
(D)
Prefrontal cortex
(BA8/9)45
5 5.26E− 17 Top validation AP
decreased gene
B. Top Dozen biomarkers from male bipolars
Gene symbol
Gene name
Probesets Discovery
(direction of change)
method/score
Prior human
genetic evidence
for suicide
Prior human brain
expression evidence
for suicide
Prior human peripheral
expression evidence
for suicide
Prioritization
Total CFG score
for suicide
Validation
ANOVA
P-value
Descriptor
Top biomarkers from discovery—step 1
BE674182 237259_at (I)
DE/4
4.00 NS Top discovery DE
increased gene
ICAM4
Intercellular adhesion molecule 4
(Landsteiner–Wiener blood group)
207194_s_at (D)
DE/4
Our previous work in males (D)
(207194_s_at) Blood4
Our previous work in females
(I)
(207194_s_at) Blood5
4.00 3.81E− 08 Top discovery DE
decreased gene
208299_at (I)
AP/4
4.00 NS Top discovery AP
increased gene
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Table 2. (Continued )
B. Top Dozen biomarkers from male bipolars
Gene symbol
Gene name
Probesets Discovery
(direction of change)
method/score
Prior human
genetic evidence
for suicide
Prior human brain
expression evidence
for suicide
Prior human peripheral
expression evidence
for suicide
Prioritization
Total CFG score
for suicide
Validation
ANOVA
P-value
Descriptor
CACNA1I
Calcium channel, voltage-dependent, T
type, alpha 1I subunit
Our previous work in males
(I)
(208299_at) Blood4
ADAL
Adenosine deaminase-like
239711_at (D)
AP/4
Our previous work in males (D)
(239711_at)
Blood4
Our previous work in females
(D)
(239711_at) Blood5
4.00 4.53E− 08 Top discovery AP
decreased gene
Top biomarkers from prioritization—step 2
HTR2A
5-Hydroxytryptamine (serotonin)
receptor 2A, G protein-coupled
244130_at (I)
DE/2
Association
29–33,46
(I)
Prefrontal cortex34
Frontal cortex35,36
10.00 NS Top prioritization
DE Increased Gene
CRHR1
Corticotropin-releasing hormone
receptor 1
214619_at (D)
DE/1
Association47–49 (I)
Pituitary50
7.00 NS Top prioritization
DE decreased gene
KSR1
Kinase suppressor of ras 1
213769_at (I)
AP/4
(I) Nucleus accumbens20 Our previous work in males
(I)
(213769_at)
Blood4
8.00 NS Top Prioritization
AP increased gene
CLYBL
Citrate lyase beta like
239683_at (D)
AP/4
(I) Brain51 Our previous work in males
(D)
(239683_at) Blood4
8.00 0.008799 Top prioritization
AP decreased gene
Top biomarkers from validation—step 3
C20orf27
Chromosome 20 open reading frame 27
218081_at (D)
DE/2
(I) Anterior Cingulate
Cortex20
Our previous work in males (D)
(218081_a) Blood4
6.00 1.09E− 34 Top validation DE
decreased gene
SAT1
Spermidine/spermine
N1-acetyltransferase 1
213988_s_at (I)
DE/2
Association52,53 (I) Prefrontal cortex (BA46)54
(D) Prefrontal cortex55
Prefrontal cortex (BA4,
BA8/9, and BA11)56
(BA44)54
(BA9)57
Our previous work in males (I)
(213988_s_at)Blood4
8.00 4.06E− 34 Top validation DE
increased gene
SPTBN1
Spectrin, beta, non-erythrocytic 1
215918_s_at (I)
AP/1
(I) Nucleus accumbens20 Our previous work in females
(I)(214856_at)Blood5
5.00 6.7E− 32 Top validation AP
increased gene
POLR2D
Polymerase (RNA) II (DNA directed)
polypeptide D
214144_at (D)
AP/1
(I)
Anterior cingulate cortex20
Our previous work in males
(D)(214144_a)Blood4
Our previous work in females
(I) (214144_at)Blood5
5.00 2.1E− 08 Top validation AP
decreased gene
Abbreviations: ANOVA, analysis of variance; AP, absent/present; DE, differential expression; NS, non-stepwise in validation. Italic P-values are nominally but not Bonferroni signiﬁcant.
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92%, P= 7.42E− 06) and, in male bipolars, the highest risk group
(AUC 96%, P= 8.03E− 08). For predicting future hospitalizations,
the results were stronger in the high anxiety subtype (AUC 79%,
P= 7.52E− 03) and in male depression (AUC 95%, P= 4.88E− 04).
Step 5: Biological vulnerability understanding
Evidence for involvement in other disorders. We conducted
Convergent Functional Genomics analyses using the Top Dozen
and Bonferroni biomarkers (Supplementary Table S5), which
suggest that a majority (89%) of suicide biomarkers are involved
in other psychiatric disorders, providing a basis for co-morbidity
and increased vulnerability. A number of biomarkers (18%) were
also involved in aging and longevity, possible substrates for our
‘life switch’ hypothesis.
Biological pathways. We conducted biological pathway analyses
using the Bonferroni validated biomarkers, which suggest that
neurotrophic factors, programmed cell death and insulin signaling
are involved in the biology of suicide (Table 4).
Networks and Interactions. We conducted STRING analyses that
revealed groups of directly interacting genes, in particular HTR2 A/
ARRB1/GSK3B, and SLC4A4/AHCYL1/AHCYL2 (Supplementary
Figure S3). These networks may have biological signiﬁcance and
could be targeted therapeutically.
Circadian. A number of top biomarkers identiﬁed by us have
biological roles that are related to the circadian clock (Supplementary
Table S5). To be able to ascertain all the genes in our dataset that
were circadian and do estimates for enrichment, we compiled from
the literature a database of all the known genes that fall into these
three categories, numbering a total of 1468 genes. Using an estimate
of about 21 000 genes in the human genome, that gives about 7% of
genes having some circadian pattern. Out of our 154 top biomarker
genes, 18 had circadian evidence (11.7%) (Supplementary Table S5),
suggesting a 1.7-fold enrichment for circadian genes. Circadian clock
abnormalities are related to mood disorders12,13 and sleep
abnormalities have been implicated in suicide.14
Enrichment in suicide completers. Of the candidate biomarkers
from the Prioritization step, 125/430 of the DE ones (29.1%) and
37/180 of the AP ones (20.6%) were Bonferroni validated in suicide
completers. There is a 1.4-fold enrichment in DE vs AP, which
suggests that completion of suicide may be due more to an
incremental change in expression of genes rather than the
complete turning on and off of genes.
Step 6: Therapeutics
Pharmacogenomics. A number of individual top biomarkers are
known to be modulated by medications in current clinical use for
treating suicidality, such as lithium (HTR2A, GSK3B, ITGB1BP1 and
BCL2), clozapine (IL6, CD164, CD47, HTR2A, PGK1, DYRK2, IFNG
and LPAR1) and omega-3 fatty acids (APOE, CD47, ACP1, GATM,
LHFP and LPAR1) (Figure 7, Table 5 and Supplementary Table S5).
In particular, HTR2A and CRYAB are at the overlap of lithium and
clozapine, and MBP is at the overlap of all three treatments
(Figure 7). Omega-3 fatty acids may be a widely deployable
preventive treatment, with minimal side effects, including in
women who are or may become pregnant. Of note, CD109, a
Bonferroni list biomarker increased in expression in suicidality in
our studies (Supplementary Table S5), has also reported to be
increased in expression by treatment of lymphoblastoid cells with
the SSRI paroxetine, and thus merits follow-up as a potentially
useful biomarker for treatment-emergent SI.
Figure 2. Step 4: Testing for Diagnostics. Best single universal biomarkers predictors. From Top Dozen List (bold) and from Bonferroni List
(combined 154 biomarkers). Bar graph shows best predictive biomarkers in each group. *Nominally signiﬁcant Po0.05. **Survives correction
for multiple comparisons testing of 154 biomarkers, Po0.000325. Table underneath the ﬁgures displays the actual number of biomarkers for
each group whose region of interest (ROC) area under the curve (AUC) P-values are at least nominally signiﬁcant. Some female diagnostic groups
are missing from the graph, as they did not have any nominally signiﬁcant biomarkers, due at least in part to the small number of cases.
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Figure 3. Step 4: Testing for Diagnostics. Universal and male bipolar biomarkers. Best individual biomarkers from Top Dozen List and from
Bonferroni List, for universal and for male bipolar. We only show biomarker results where region of interest (ROC) area under the curve (AUC)
P-values are at least nominally signiﬁcant and AUCs are at least 0.6 (60%). (a) Circos plot depicting the best individual biomarker predictions
for suicidal ideation (SI) state in the independent cohort (across all participants, in subtypes and personalized by gender and diagnosis), using
universal biomarkers. (b) Circos plot depicting the best individual biomarker predictions for future hospitalizations for suicidality in the ﬁrst
year following testing in the independent cohort ( across all participants, in subtypes and personalized by gender and diagnosis), using
universal biomarkers. (c) Circos plot depicting the best individual biomarker predictions for SI state in the independent male bipolar sub-
cohort, using universal biomarkers and male bipolar biomarkers. (d) Circos plot depicting the best individual biomarker predictions for future
hospitalizations for suicidality in the ﬁrst year following testing in the independent male bipolar sub-cohort, using universal biomarkers and
male bipolar biomarkers. The circumference bands represent and are proportional to the number of participants in each cohort. The ribbons
represent and are proportional to the AUC of the predictions. Table underneath the ﬁgures displays the actual numerical results.
Precision medicine for suicidality
AB Niculescu et al
1258
Molecular Psychiatry (2017), 1250 – 1273
Table 3. Step 4: Diagnostics
A. SI state
Predictors Cohort Participants visits with high
SI/participants visits total
ROC AUC/P-value Suicidality severity (HAMD SI score)
correlation R/P-value
T-test P-value
Universal
Best Biomarkers
SLC4A4 All 52/544 0.64/3.83E − 04 0.13/1.54E − 03 1.50E− 03
CLN5 All 52/544 0.65/1.86E −04 − 0.11/6.13E − 03 3.90E− 04
BioM 148 Panel (Bonferroni List) All 52/544 0.61/6.18E − 03 0.069/5.33E− 02 1.77E− 02
BioM 12 Panel (Top Dozen List) All 52/544 0.61/3.66E − 03 0.12/3.02E − 03 3.08E− 03
BioM 2 Panel (SLC4A4 and CLN5) All 52/544 0.66/4.92E −05 0.14/7.82E − 04 1.90E− 04
Phenes
Mood All 52/544 0.77/5.93E −11 − 0.38/3.17E − 20 1.95E− 10
Anxiety All 52/544 0.77/3.43E −11 0.31/8.60E − 14 2.03E–12
Mood and Anxiety (SASS) All 52/544 0.81/5.55E −14 0.40/3.66E − 22 3.57E− 14
CFI-S All 52/523 0.86/9.98E −18 0.43/1.03E − 24 5.46E− 16
Mood and Anxiety and CFI-S All 52/523 0.89/2.59E −20 0.49/1.60E − 33 1.08E− 18
Phenes and Biomarkers
Mood and Anxiety and CFI-S and BioM 148 All 52/523 0.89/1.36E −20 0.49/2.84E − 33 2.88E− 18
Mood and Anxiety, and CFI-S and BioM 12 (UP-Suicide) All 52/523 0.90/3.87E − 21 0.50/5.91-35 3.42E− 19
Mood and Anxiety, and CFI-S and BioM2 All 52/523 0.89/4.56E −21 0.50/4.07E − 34 2.83E− 18
Male Bipolar
Best Biomarkers
SPTBN1 M-BP 12/130 0.72/6.62E − 03 0.21/8.54E − 03 9.05E− 03
C7orf73 M-BP 12/130 0.75/2.38E − 03 − 0.17/2.76E − 02 1.08E− 04
BioM 54 Panel (Bonferroni List) M-BP 12/130 0.49/5.29E − 01 0/4.90E− 01 7.12E− 01
BioM 12 Panel (Top Dozen List) M-BP 12/130 0.57/2.08E − 01 0.08/1.78E − 01 8.79E− 02
BioM 2(SPTBN1 and C7orf73) M-BP 12/130 0.80/3.54E − 04 0.23/4.77E − 03 6.62E− 05
Phenes
Mood M-BP 12/130 0.8/3.65E − 04 − 0.47/6.83E − 09 1.65E− 03
Anxiety M-BP 12/130 0.86/2.19E − 05 0.41/7.09E − 07 1.91E− 05
Mood and Anxiety (SASS) M-BP 12/130 0.86/1.66E − 05 0.5/7.15E− 10 5.66E− 05
CFI-S M-BP 12/128 0.92/1.10E − 06 0.5/6.11E− 10 1.31E− 06
Mood and Anxiety, and CFI-S M-BP 12/128 0.94/2.82E − 07 0.61/1.24E − 14 3.01E− 06
Phenes and Biomarkers
Mood and Anxiety, and CFI-S and BioM 54 M-BP 12/128 0.93/5.30E − 07 0.61/1.78E − 14 5.54E− 06
Mood and Anxiety, and CFI-S and BioM 12 M-BP 12/128 0.95/1.62E − 07 0.62/1.92E− 15 8.31E− 07
Mood and Anxiety, and CFI-S and BioM 2 M-BP 12/128 0.97/5.14E − 08 0.64/2.29E − 16 2.59E− 07
B. Future hospitalizations for suicidality in the ﬁrst year following assessment
Predictors Cohort Participants visits with future
hospitalizations for suicidality within
the ﬁrst year/particpants visits total
ROC AUC/P-value Frequency of future hospitalizations
for suicidality within the ﬁrst year
correlation R/P-value
T-test
P-value
Cox regression
hazard ratio /P-value
Universal
Best Biomarkers
PSME4 All 38/471 0.59/2.62E− 02 0.08/4.12E − 02 6.20E− 02 1.23/ 1.56E− 01
AK2 All 38/471 0.60/2.31E− 02 − 0.06/9.70E − 02 9.39E− 03 1.35/ 7.22E− 02
BioM 148 Panel (Bonferroni List) All 38/471 0.52/3.37E− 01 − 0.02/6.67E − 01 4.18E− 01 1.09/8.27E − 01
BioM 12 Panel (Top Dozen List) All 38/471 0.58/4.20E− 02 0.05/1.47E − 01 5.02E− 02 1.88/1.41E − 01
BioM 2 Panel (PSME4 and AK2) All 38/471 0.65/1.10E− 03 0.10/1.29E − 02 1.35E− 03 1.68/0.018
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Table 3. (Continued )
B. Future hospitalizations for suicidality in the ﬁrst year following assessment
Predictors Cohort Participants visits with future
hospitalizations for suicidality within
the ﬁrst year/particpants visits total
ROC AUC/P-value Frequency of future hospitalizations
for suicidality within the ﬁrst year
correlation R/P-value
T-test
P-value
Cox regression
hazard ratio /P-value
Phenes
Mood All 38/471 0.65/1.00E− 03 − 0.16/3.63E− 04 1.03E− 03 1.69/1.47E − 03
Anxiety All 38/471 0.69/3.70E− 05 0.16/3.43E − 04 2.30E− 04 1.82/2.62E − 04
Mood and Anxiety (SASS) All 38/471 0.71/9.78E− 06 0.18/4.89E − 05 7.73E− 05 1.45/ 8.11E− 05
CFI-S All 38/470 0.75/1.79E− 07 0.2/5.11E− 06 1.40E− 06 2.02/7.11E − 07
Mood and Anxiety and CFI-S All 38/470 0.76/6.34E− 08 0.22/4.18E − 07 2.22E− 06 1.40/1.13E − 07
HAMD SI All 35/458* 0.81/5.27E− 10 0.40/1.57E − 19 2.64E− 06 2.10/1.11E − 15
Mood and Anxiety, and CFI-S and HAMD SI All 35/458* 0.82/9.96E− 11 0.35/4.11E − 15 4.34E− 08 1.36/1.83E − 13
Phenes and Biomarkers
Mood and, Anxiety and CFI-S and BioM 148 All 38/470 0.76/6.65E− 08 0.21/1.29E − 06 2.29E− 06 1.37/2.01E − 07
Mood and Anxiety, and CFI-S and BioM 12 (UP-Suicide) All 38/470 0.77/2.87E − 08 0.23/2.81E− 07 9.11E− 07 1.40/5.31E− 08
Mood and Anxiety, and CFI-S and BioM 2 All 38/470 0.76/3.87E− 08 0.24/1.17E − 07 1.02E− 06 1.39/3.98E − 08
Mood and Anxiety, and CFI-S and HAMD SI, and BioM 2 All 35/458* 0.82/9.38E− 11 0.35/3.20E − 15 3.39E− 08 1.35/1.83E − 13
Male bipolars
Best biomarkers
PTEN M-BP 4/120 0.9/3.27E − 03 0.22/6.76E − 03 3.12E− 02 1.73/2.73E − 02
RNF6 M-BP 4/120 0.82/1.58E− 02 − 0.14/5.89E− 02 9.14E− 03 6.24/7.19E − 02
BioM 54 Panel (Bonferroni List) M-BP 4/120 0.75/4.23E− 02 0.11/1.23E − 01 4.71E− 02 4.58/2.52E − 01
BioM 12 Panel (Top Dozen List) M-BP 4/120 0.56/3.41E− 01 0.05/2.85E − 01 3.08E− 01 2.57/5.73E − 01
BioM 2 (PTEN and RNF6) M-BP 4/120 0.94/1.50E− 03 0.23/5.17E − 03 3.06E− 03 2.68/1.19E − 02
Phenes
Mood M-BP 4/120 0.69/1.04E− 01 − 0.14/6.08E− 02 1.75E− 01 2.10/1.32E − 01
Anxiety M-BP 4/120 0.70/9.29E− 02 0.12/9.74E − 02 1.12E− 01 1.87/2.09E − 02
Mood and Anxiety (SASS) M-BP 4/120 0.72/7.19E− 02 0.15/5.27E − 02 1.34E− 01 1.52/1.18E − 01
CFI-S MBP 4/120 0.80/2.10E− 02 0.15/5.22E − 02 3.46E− 03 1.95/1.21E − 01
Mood and Anxiety, and CFI-S M-BP 4/120 0.78/2.77E− 02 0.18/2.36E − 02 6.78E− 02 1.41/5.54E − 02
Phenes and biomarkers
Mood and Anxiety, and CFI-S and BioM 54 M-BP 4/120 0.81/1.64E− 02 0.2/1.61E− 02 5.13E− 02 1.45/4.04E − 02
Mood and Anxiety, and CFI-S and BioM 12 M-BP 4/120 0.79/2.59E − 02 0.19/1.88E− 02 7.92E− 02 1.44/4.72E− 02
Mood and Anxiety, and CFI-S and BioM 2 M-BP 4/120 0.86/7.02E− 03 0.25/3.48E − 03 2.22E− 02 1.55/1.18E− 2
Biomarkers, phenes and combined predictions. Top increased and decreased individual predictive biomarkers. Underlined are individual biomarkers from the Top Dozen list, the others are from the Bonferroni
list. For Universal, the panel of Top Dozen biomarkers is called BioM 12, and the panel of Bonferroni biomarkers is called BioM148, reﬂecting the number of markers in the panel. For Male Bipolar, the panel of Top
Dozen biomarkers is called BioM 12, and the panel of Bonferroni biomarkers is called BioM54, reﬂecting the number of markers in the panel. Bold, Bonferroni signiﬁcant in the diagnostic testing. Italic, a priori
primary endpoint (UP-Suicide). Abbreviations: AUC, area under the curve; BP, bipolar; CFI-S, Convergent Functional Information for Suicidality; ROC, receiver operating characteristic; SASS, Simpliﬁed Affective
State Scale; SI, suicidal ideation. Bold P-value of AUC survives correction for multiple testing for predictions. ROC AUC is our a priori primary predictive tool. HAMD SI is the suicide rating question from the
Hamilton Rating Scale for Depression.*Smaller cohort, as not everybody had HAMD SI information.
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New drug discovery/repurposing. Bioinformatic analyses using
the gene expression signature of panels of top biomarkers
identiﬁed new potential therapeutics for suicidality, such as
ebselen (a lithium mimetic with anti-inﬂammatory and antioxidant
properties),15,16 piracetam (a nootropic cyclic derivative of
GABA),17 chlorogenic acid (an antioxidant polyphenol from
coffee)18 and metformin (an antidiabetic and possible longevity
promoting drug)19 (Table 6).
Phenomenology. SASS can be used to identify possible subtypes
of suicidality ( low mood, high anxiety, combined and non-
affective) that may have practical utility, as we have shown in this
Figure 4. Convergent Functional Information for Suicide (CFI-S) testing. Testing in a large cohort that combines the discovery and test cohorts
used for biomarker work. CFI-S was developed independently of any data from this study, by compiling known socio-demographic and
clinical risk factors for suicide. It is composed of 22 items that assess the inﬂuence of mental health factors, as well as of life satisfaction,
physical health, environmental stress, addictions and cultural factors known to inﬂuence suicidal behavior, as well as two demographic factors,
age and gender. (a) Prediction of high suicidal ideation (HAMD SI4= 2). (b) Prediction of future hospitalizations due to suicidality within one
year of follow-up. Table under a depicts individual items and their ability to differentiate between participants with No SI, Intermediate SI and
High SI. Stepwise refers to gradual increase between the three groups (No SI, Intermediate SI, High SI). Table under b depicts individual items
and their ability to differentiate between participants with and without future hospitalizations due to suicidality. Different items are positive in
different individuals, providing leads for targeted (psycho)therapeutic interventions.
Figure 5. Predicting suicidality using a broad-spectrum predictor (UP-Suicide), which is an algorithm combining phenotypic information
measures (Convergent Functional Information for Suicide (CFI-S) and Simpliﬁed Affective State Scale (SASS) (anxiety and mood)) and a panel
of the Top Dozen universal biomarkers (BioM 12). (a) Model of various factors involved in suicidality (environmental stressors, life failures, body
health issues, mind frailty, addiction problems and cultural examples). CFI-S, SASS and Biomarker panel are the components of our UP-Suicide.
SA, suicide attempt; SI, suicidal ideation. (b) UP-Suicide predictions in the independent testing cohort, for High SI and for future
hospitalizations for suicidality in the ﬁrst year. (c) A dimensional view of risk stratiﬁcation using phenotypic information measures and example
of two high-risk participants. We calculated Euclidian distances from origin. Participant phchp158 is a divorced African American male in his
late 20s with a long history of schizoaffective disorder, bipolar type and cannabis abuse. He was tested by us once (v1), while he was
hospitalized for a suicide attempt by hanging. In the 5 years following testing, he has had two additional hospitalizations for suicidality: one
for SI and one for attempt by overdose. He has had two hospitalizations for psychosis exacerbation without suicidality during this time span as
well. Moved out of state, lost to follow-up since December 2015. Participant phchp328 was a divorced Caucasian female in her late 30s with a
long history of depression, post-traumatic stress disorder (PTSD), borderline personality disorder and polysubstance abuse/dependence. She
was ﬁrst tested by us (v1) while inpatient for SI. Over the next year she subsequently had six psychiatric hospitalizations for suicidality: ﬁve due
to SI and one due to a suicidal attempt by overdose. She also had one hospitalization for opioid withdrawal and depression during this time
span as well. She committed suicide by overdose with pills, leaving behind a suicide note addressed to her mother. Her UP-Suicide score at
Visit 1, composed of the panel of top dozen biomarkers (BioM12) scores and phenomic measures scores (CFI-S and SASS), was at the 100% of
the scores of all the psychiatric participants visits in the current study. That testing was conducted during an inpatient hospitalization due to
SI. Although her scores did improve at subsequent outpatient testing visits (Visits 2 and 3), this high watermark score indicated her high risk.
After the last testing visit in our study, she had four subsequent psychiatric hospitalizations: three due to SI and one for opioid withdrawal/
detox (the last one, which ended 2 weeks before the date of her committing suicide (T)).
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work. The top CFI-S items distinguishing high SI from intermediate
SI and no SI states were dissatisfaction with one’s life, social
isolation and lack of coping skills in the face of stress. The top
CFI-S items distinguishing those that had future hospitalizations
for suicidality versus those that did not were past history of
suicidality, command auditory hallucinations and social isolation
(Figure 4). This provides empirical evidence that, in general,
reducing social isolation is a good behavioral therapeutic
intervention for preventing suicidality. In different individuals
different CFI-S items are positive, providing avenues for tailored
and targeted (psycho)therapeutic interventions.
Final summation: overall evidence for establishment of clinical
utility
For the universal biomarkers identiﬁed by us, combining all the
available evidence from this current work and the published
literature, into a convergent functional evidence score, brings to
Figure 5. For caption see page on 1261.
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the fore biomarkers that might have clinical utility, for future
studies in the ﬁeld (Figures 8, 9, and Supplementary Table S7).
Studies in male bipolars: personalization versus universal
As a comparator to the universal approach across gender and
diagnoses, we also conducted within-participant longitudinal
biomarker discovery analyses in male bipolars only, the largest
subgroup (n= 20 participants, 65 testing visits) in our discovery
cohort. Male bipolars are the highest risk group for suicide
clinically and have been the focus of earlier suicide biomarker
studies by us, with an N (n= 9) that was less than half of the
current one. The discovery step was followed by prioritization and
by validation in male suicide completers. We reproduced and
Figure 6. UP-Suicide across all, by subtypes and personalized by gender/diagnosis. UP-Suicide composed of the panel of the Top Dozen
universal biomarkers (BioM 12), Convergent Functional Information for Suicide (CFI-S) and Simpliﬁed Affective State Scale (SASS) (anxiety and
mood). Plot depicts area under the curve (AUC) for the UP-Suicide predicting suicidal ideation (SI) and hospitalizations within the ﬁrst year in
all participants, as well as separately in subtypes, and by gender and diagnosis (Gender/Dx). Two asterisks indicate the comparison survived
Bonferroni correction for all the multiple comparisons depicted. A single asterisk indicates nominal signiﬁcance of Po0.05. Bold outline
indicates that the UP-Suicide was synergistic to its components, that is, performed better than the gene expression biomarkers or phenomic
measures individually. Table contains descriptive statistics for all participants together, as well as separately by subtypes and by gender/dx. For
female gender/dx groups, only the female bipolar subgroup had enough participants to yield at least a nominally signiﬁcant AUC. Bold
indicates the measure survived very stringent Bonferroni correction for all the multiple comparisons in our whole study (2737 biomarkers and
phenes, resulting in a Bonferroni cutoff of 1.83E− 05). We also show Pearson’s correlation data in the SI test cohort for HAMD-SI vs UP-Suicide,
as well as Pearson’s correlation data in the hospitalization test cohort for frequency of hospitalizations for suicidality in the ﬁrst year and for
frequency of hospitalizations for suicidality in all future available follow-up interval (which varies among participants, from 0.40 to 10.42 years).
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Table 4. Biological pathways
A. Universal biomarkers
Universal pathways DAVID GO functional annotation biological processes KEGG pathways Ingenuity pathways
# Term Count % P-value Term Count % P-value Top Canonical
Pathways
P-value Overlap
Validation Bonferroni signiﬁcant
(n= 130 genes, 148 probe sets)
1 Regulation of neurogenesis 8 6.6 2.10E− 04 Tryptophan metabolism 4 0.2 1.10E− 02 Protein kinase A
signaling
4.36E− 06 0.031
12/386
2 Negative regulation of apoptosis 11 9 2.60E− 04 Neurotrophin signaling
pathway
6 0.3 1.40E− 02 IGF-1 signaling 2.86E− 05 0.062
35/582
3 Negative regulation of
programmed cell death
11 9 2.90E− 04 Insulin signaling pathway 6 0.3 1.90E− 02 Gap junction
signaling
4.66E− 05 0.045
7/155
4 Negative regulation of cell death 11 9 3.00E− 04 Butanoate metabolism 3 0.2 5.90E− 02 Renin-angiotensin
signaling
5.52E− 05 0.055
6/109
5 Regulation of cell morphogenesis 7 5.7 3.90E− 04 Endocytosis 6 0.3 6.10E− 02 Hepatic cholestasis 5.93E− 05 0.043
7/161
B. Male Bipolar biomarkers
Male bipolar pathways DAVID GO functional annotation biological processes KEGG pathways Ingenuity pathways
Validation Bonferroni
signiﬁcant (n= 50 genes, 54
probe sets)
# Term Count % P-value Term Count % P-value Top Canonical Pathways P-value Overlap
1 Negative regulation of neuron
differentiation
7 14.6 9.30E− 06 mTOR signaling pathway 3 6.2 1.60E− 02 G-protein coupled receptor
signaling
1.14E− 14 0.113
29/256
2 Negative regulation of
neurogenesis
7 14.6 3.60E− 05 Small cell lung cancer 3 6.2 3.20E− 02 CREB signaling in neurons 1.98E− 14 0.14
24/171
3 Negative regulation of nervous
system development
7 14.6 5.50E− 05 Leukocyte transendothelial
migration
3 6.2 5.80E− 02 Neuropathic pain signaling
in dorsal horn neurons
4.82E− 13 0.18
18/100
4 Positive regulation of protein
localization to plasma membrane
4 8.3 1.10E− 04 Sphingolipid signaling
pathway
3 6.2 6.00E− 02 14-3-3-mediated signaling 7.79E− 12 0.154
18/117
5 Positive regulation of protein
localization to cell periphery
4 8.3 1.10E− 04 NA NA NA NA Gap junction signaling 1.50E− 11 0.129
20/155
Abbreviations: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; NA, not applicable.
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expanded some of our previous biomarker ﬁndings in bipolar
disorder (Table 2B, Figure 3 and Supplementary Figure S4). We
tested the male bipolar derived top dozen biomarkers (Table 2B)
and all the biomarkers that survived Bonferroni correction after
the validation step (Supplementary Table S8), for prediction of SI
and for prediction of future psychiatric hospitalizations due to
suicidality in the male bipolar subgroup (n= 49) in the indepen-
dent test cohort (Figure 3 and Supplementary Table S10). We were
successful in the identiﬁcation of predictive biomarkers that might
be more speciﬁc for suicidality in male bipolars. We also examined
whether biomarkers discovered using just male bipolar subjects
yields even better predictors for male bipolar subjects than using
the universal biomarkers and found that to be the case for trait
(hospitalizations) predictions (Figure 3). A number of top male
bipolar biomarkers identiﬁed by us are targets of medications in
current clinical use for treating suicidality (Supplementary Table
S12). Bioinformatic drug repurposing analyses using the gene
expression biosignature of panels of top biomarkers identiﬁed
new potential therapeutics for suicidality in male bipolars
(Table 6C and D). The top compounds identiﬁed include betulin
(a natural plant compound with longevity and anticancer proper-
ties), naproxen (a non-steroidal anti-inﬂammatory), as well as
chlorphenesin and baclofen (central nervous system acting
muscle relaxants used to treat pain and spasms). Combining all
the available evidence from this current work and the published
literature, into a convergent functional evidence score (Figure 10
and Supplementary Table S13), leads to a prioritization of
biomarkers for future studies in the ﬁeld.
DISCUSSION
Was our quest for more universal predictors or our quest for more
personalized predictors more informative? The answer seems to
be both, for different and complementary reasons. The universal
approach may illuminate a more speciﬁc core biology for suicide,
the personalized approach by gender and diagnosis may provide
a more sensitive and context dependent applicability. The new
subtypes we identiﬁed seem to have some utility (Figure 2 and
Supplementary Figure S2). They merit future exploration and are
easy to assess in the general population using our SASS
questionnaire/app.
The current work is more comprehensive in design and larger in
size than our previous studies.4,5,7 We used a systematic discovery,
prioritization, validation, and testing approach.2 For discovery,
we used a hard to accomplish but powerful within-participant
design, with an N of 66 participants with 193 visits. A within-
participant design factors out genetic variability, as well as some
medications, lifestyle and demographic effects on gene expression,
permitting identiﬁcation of relevant signal with N as small as 1.6
Another beneﬁt of a within-participant design may be accuracy/
consistency of self-report of psychiatric symptoms (‘phene expres-
sion’), similar in rationale to the signal detection beneﬁts it provides
in gene expression. Just the male bipolar sub-component alone had
twice as many participants in discovery (20 vs 9) and four times as
many participants in validation (38 vs 9) than our original
breakthrough study on suicide biomarkers in male bipolars
published in 2013.7 Out of the six Bonferroni-validated biomarkers
in that study,7 four were also Bonferroni validated in the current
study (SAT1, BF114768/UBA6, MARCKS and PTEN), at the exact
same probe sets. Moreover, LHFP, a biomarker that just missed the
Bonferroni cutoff in the original male bipolar work,7 is a universal
Bonferroni validated biomarker in the current work, with predictive
ability for SI state in the high anxiety subtype (AUC of 78%, P-value
1.95E− 02), female bipolars (AUC of 79%, P-value 4.6E− 02) and
male depression (AUC 69%, P-value 3.32E− 02), as well as very
strong predictive ability for future hospitalizations for suicidality in
male depression (AUC 98%, P-value 2.54E− 04) (Figures 2 and 3).
LHFP (lipoma HMGIC fusion partner), increased in expression in
blood in our studies, is also previously reported to be increased in
expression in brains of suicide completers.20 Of note, SAT1, which is
increased in expression in suicide in our studies, degrades
spermidine, a compound recently implicated in longevity.21 This
is consistent with our overall ‘life switch’22 hypothesis.
Our Bayesian-like Convergent Functional Genomics platform
used for prioritizing ﬁndings following the discovery step ensures
robust built in reproducibility, as it is based on corroborating
evidence by other groups, using different methodologies and
cohorts. No single approach or study is perfect and datasets are
especially powerful in combination.
The phenotypic measures apps scores by themselves (‘digital
biomarkers’) were more precise predictors than the blood
biomarkers by themselves, although their combination did show
some synergy (Table 3). However, blood biomarkers may have
usefulness for objective diagnostic testing and patient stratiﬁca-
tion, over and above clinical classiﬁcations. This may be
particularly important when individuals choose not to share how
they feel and do not seek help. We observed such possible
discrepancies for different subtypes and gender/diagnostic groups
(Supplementary Figure S2).
In terms of how our biomarker discoveries might be applied in
clinical laboratory settings, we suggest that one might combine the
best universal biomarkers with the best personalized biomarkers, to
have the best of both worlds. In practice, every new patient tested
would be normalized against the database of similar patients
already tested and compared with them for ranking and risk
prediction purposes, regardless of whether a platform such as
Affymetrix or a more targeted one is used in the end clinically. As
databases get larger, normative population levels can and should
be established, similar to any other laboratory measures. Moreover,
longitudinal monitoring of changes in biomarkers within an
individual, measuring most recent slope of change, maximum
levels attained and maximum slope of change attained, may be
even more informative than simple cross-sectional comparisons of
levels within an individual with normative populational levels and is
the focus of future studies by our group.
Biomarkers may also be useful for patient stratiﬁcation and
measuring response to treatment (pharmacogenomics) (Figure 7,
Figure 7. Step 6: Therapeutics. Pharmacogenomics. Individual
biomarkers modulated by medications used in the treatment of
suicidality. Universal biomarkers, bold; male bipolar, italic; both, bold
and italic and underlined. Red, increased in expression in suicidality.
Blue, decreased in expression in suicidality.
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Table 5. Step 6: Therapeutics
Discovery
(change)
method/score
Prioritization total
CFG score for
suicide
Validation
ANOVA
P-value
Omega-3 Lithium Clozapine Antidepressants Other mood
stabilizers
Other other antipsychotics
Universal Top Dozen biomarkers
HTR2A
5-Hydroxytryptamine
(serotonin) receptor 2A, G
protein-coupled
(I)
DE/2
10 NS (D)
NT2.D1 cells
Lithium58
(D)
PFC
Clozapine59,60
Blocked by:
Mirtazapine,
Amitriptyline
(D)
NT2.D1 cells
Valproate58
(D)
PFC Haloperidol59
Blocked by: Paliperidone,
Risperidone, Iloperidone,
Asenapine, Cariprazine,
Lurasidone, Quetiapine,
Olanzapine
IFNG
Interferon, gamma
(D)
AP/1
9 NS (I)
Saliva, Blood Olanzapine,
Risperidone, Quetiapine,
Aripiprazole61
SLC4A4
Solute carrier family 4
(sodium bicarbonate
cotransporter), member 4
(I)
AP/1
7 7.74E− 05 (D)
AMY, CP
Valproate62
CCL28
Chemokine (C–C motif )
ligand 28
(D)
AP/4
4 NS (I) Lymphoblastoid
cell line Paroxetine63
Male bipolar top dozen biomarkers
HTR2A
5-Hydroxytryptamine
(serotonin) receptor 2A, G
protein-coupled
(I)
DE/2
10 NS (D)
NT2.D1 cells
Lithium58
(D)
PFC
Clozapine59,60
Blocked by:
Mirtazapine,
Amitriptyline
(D)
NT2.D1 cells
Valproate58
(D)
PFC Haloperidol59
Blocked by: Paliperidone,
Risperidone, Iloperidone,
Asenapine, Cariprazine,
Lurasidone, Quetiapine,
Olanzapine
SAT1
Spermidine/spermine
N1-acetyltransferase 1
(I)
DE/2
8 4.06E− 34 (D)
blood
Omega 364
SPTBN1
Spectrin, beta, non-
erythrocytic 1
(I)
AP/1
5 6.7E− 32 (D)
blood
Omega 364
Pharmacogenomics. Top Dozen lists biomarkers in our datasets that are targets of existing drugs and are modulated by them in opposite direction. Abbreviations: ANOVA, analysis of variance; CFG, Convergent
Functional Genomics; NS, non-stepwise in validation; PFC, prefrontal cortex.
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Table 6. Step 6: Therapeutics. New drug discovery/repurposing
A. CMAP analysis with the universal Top Dozen biomarkers signature
Rank Cmap name Dose Cell Score
6086 Torasemide 11 μM MCF7 − 0.9
6087 Tenoxicam 12 μM MCF7 − 0.9
6088 Halcinonide 9 μM PC3 − 0.902
6089 Tretinoin 1 μM MCF7 − 0.913
6090 NU-1025 100 μM MCF7 − 0.915
6091 Abamectin 5 μM MCF7 − 0.919
6092 Prednicarbate 8 μM MCF7 − 0.921
6093 Tolmetin 13 μM MCF7 − 0.924
6094 Alprostadil 10 μM PC3 − 0.925
6095 Amoxapine 13 μM MCF7 − 0.927
6096 Fenbufen 16 μM MCF7 − 0.929
6097 Sertaconazole 8 μM PC3 − 0.93
6098 Oxybuprocaine 12 μM MCF7 − 0.961
6099 Piracetam 28 μM MCF7 − 0.973
6100 Ebselen 15 μM PC3 − 1
B. CMAP analysis with the universal Bonferroni biomarkers signature
Rank Cmap name Dose Cell Score
6068 Fluoxetine 12 μM HL60 − 0.812
6069 Betulin 9 μM HL60 − 0.812
6070 Netilmicin 3 μM HL60 − 0.82
6071 Dl-alpha tocopherol 9 μM HL60 − 0.821
6072 Haloperidol 10 μM HL60 − 0.823
6073 Streptozocin 15 μM HL60 − 0.824
6074 Hesperidin 7 μM HL60 − 0.824
6075 Calcium folinate 8 μM MCF7 − 0.825
6076 Harpagoside 8 μM MCF7 − 0.826
6077 Trimipramine 10 μM HL60 − 0.836
6078 Dapsone 16 μM HL60 − 0.844
6079 Fulvestrant 10 nM HL60 − 0.845
6080 Rilmenidine 8 μM HL60 − 0.845
6081 Atractyloside 5 μM HL60 − 0.849
6082 Tenoxicam 12 μM HL60 − 0.851
6083 Chlorpromazine 11 μM HL60 − 0.852
6084 Harman 18 μM HL60 − 0.858
6085 Homatropine 11 μM HL60 − 0.863
6086 Ramifenazone 14 μM HL60 − 0.864
6087 Clozapine 10 μM HL60 − 0.866
6088 Diphenhydramine 14 μM HL60 − 0.873
6089 Metrizamide 5 μM HL60 − 0.874
6090 Prochlorperazine 7 μM HL60 − 0.874
6091 Pirenperone 10 μM HL60 − 0.876
6092 Hydrastinine 16 μM HL60 − 0.88
6093 Carbimazole 21 μM HL60 − 0.884
6094 Asiaticoside 4 μM HL60 − 0.886
6095 Procainamide 15 μM HL60 − 0.894
096 Ozagrel 15 μM HL60 − 0.903
6097 Adiphenine 11 μM HL60 − 0.923
6098 Merbromin 5 μM HL60 − 0.924
6099 Metformin 24 μM HL60 − 0.983
6100 Chlorogenic acid 11 μM HL60 − 1
C. CMAP analysis with the male bipolar Top Dozen biomarkers signature
Rank Cmap name Dose Cell Score
6086 Harmaline 14 μM MCF7 − 0.822
6087 Foliosidine 13 μM MCF7 − 0.834
6088 3-Nitropropionic acid 10 μM MCF7 − 0.844
6089 Biperiden 11 μM PC3 − 0.844
6090 Carisoprodol 15 μM HL60 − 0.848
6091 Nalidixic acid 15 μM MCF7 − 0.861
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Table 6. (Continued )
C. CMAP analysis with the male bipolar Top Dozen biomarkers signature
Rank Cmap name Dose Cell Score
6092 Eucatropine 12 μM PC3 − 0.869
6093 Solasodine 10 μM PC3 − 0.873
6094 Dicoumarol 12 μM PC3 − 0.875
6095 Pivampicillin 9 μM MCF7 − 0.879
6096 Gabexate 10 μM PC3 − 0.885
6097 Dacarbazine 22 μM PC3 − 0.892
6098 Prestwick-692 7 μM MCF7 − 0.927
6099 Carteolol 12 μM HL60 − 0.946
6100 Betulin 9 μM HL60 − 1
D. CMAP analysis with the male bipolar Bonferroni biomarkers signature
Rank Cmap name Dose Cell Score
6068 Valproic acid 50 μM MCF7 − 0.799
6069 Ondansetron 12 μM PC3 − 0.802
6071 NU-1025 100 μM MCF7 − 0.807
6073 Glycopyrronium bromide 10 μM PC3 − 0.814
6074 Triﬂupromazine 10 μM HL60 − 0.817
6075 Suxibuzone 9 μM MCF7 − 0.819
6076 Mepyramine 10 μM MCF7 − 0.822
6079 Hydrocortisone 11 μM MCF7 − 0.837
6080 Benfotiamine 9 μM PC3 − 0.839
6082 Deferoxamine 6 μM PC3 − 0.841
6084 Homatropine 11 μM MCF7 − 0.845
6085 Nifedipine 12 μM PC3 − 0.849
6086 Alpha-ergocryptine 7 μM MCF7 − 0.862
6088 Meclozine 9 μM MCF7 − 0.875
6089 Acacetin 14 μM PC3 − 0.882
6095 Fenoprofen 7 μM PC3 − 0.933
6096 CP-690334-01 1 μM MCF7 − 0.936
6097 Baclofen 19 μM PC3 − 0.94
6098 Chlorambucil 13 μM MCF7 − 0.945
6099 Naproxen 16 μM PC3 − 0.96
6100 Chlorphenesin 16 μM HL60 − 1
Connectivity Map65,66 (CMAP) analysis, drugs that have opposite gene expression proﬁle effects to our suicide biomarkers signatures. A score of − 1 indicates
the perfect opposite match, that is, the best potential therapeutic for suicidality. Underlined, drugs known to treat mood disorders and suicidality, which thus
serve as a de facto positive control for our approach. Bold means top compounds of interest, pharmaceutical and natural.
Figure 8. Convergent functional evidence—multiple steps for identiﬁcation and establishment of clinically utility of biomarkers.
Precision medicine for suicidality
AB Niculescu et al
1268
Molecular Psychiatry (2017), 1250 – 1273
Figure 9. Universal biomarkers—convergent functional evidence (CFE) for involvement in suicidality. Top Dozen and Bonferroni biomarkers.
Post-hoc summation of all the evidence form discovery, validation, prioritization and testing (for state—SI and for trait-future hospitalizations),
along with evidence for involvement in other psychiatric disorders and for being a target of drugs. This prioritization highlights for future
studies biomarkers that may have broad applicability in the ﬁeld, for diagnostics and therapeutics. ASD, autism spectrum disorder; BP, bipolar;
MDD, major depressive disorder; PTSD, post-traumatic stress disorder; SZ, schizophrenia.
Precision medicine for suicidality
AB Niculescu et al
1269
Molecular Psychiatry (2017), 1250 – 1273
Figure 10. Male bipolar biomarkers—convergent functional evidence for involvement in suicidality. Top Dozen and Bonferroni biomarkers.
Post-hoc summation of all the evidence form discovery, validation, prioritization and testing, along with evidence for involvement in other
psychiatric disorders and for being a target of drugs. This prioritization highlights for future studies biomarkers that may have broad
applicability in the ﬁeld, for diagnostics and therapeutics. ASD, autism spectrum disorder; BP, bipolar; MDD, major depressive disorder; PTSD,
post-traumatic stress disorder; SZ, schizophrenia.
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Table 5 and Supplementary Table S5), and drug discovery/
repurposing (Table 6). In terms of therapeutics, ebselen, although
discovered decades ago for other indications and shown to be
safe and well tolerated in human studies, has been recently
proposed as a treatment for bipolar disorder.15 The fact that it was
the compound that had the strongest/perfect score on the
Connectivity Map analyses as having the opposite gene expres-
sion effects to the biosignature of the Top Dozen universal
biomarkers for suicidality is a tantalizing result. Piracetam and
chlorogenic acid are compounds that can be classiﬁed as
nutraceuticals, already in use and relatively safe and innocuous,
which may facilitate adoption, along with omega-3 fatty acids, for
pre-emptive population-level approaches. Metformin, besides
being originally an antidiabetic compound, may act on promoting
longevity by mimicking the effects of calorie restriction. The fact
that it may have anti-suicidal properties is consistent with a
possible suicide/longevity ‘life switch’ machinery, as previously
proposed by us.22 Interestingly, clozapine and ﬂuoxetine, two
known medications used to treat suicidality, were identiﬁed by our
bioinformatics approach, but with lower priority than metformin
(Table 6B). They serve as reassuring positive controls.
The biomarkers also provide a window toward a more nuanced
understanding of the biology of suicide. The universal biomarkers
may be pointing to a core common biology, such as inﬂammation
and stress response, and the balance between neuronal cell
survival and apoptosis, that is, a cellular level ‘life switch’. The
personalized biomarkers (such as male bipolar biomarkers), may
be more reﬂective of the psychiatric co-morbidity driving
suicidality and medication effects in different gender/diagnostic
groups, such as mTOR signaling in male bipolars, which is
modulated by mood regulating drugs, including a new one
(ketamine),23 which also shows promise for treating suicidality.24
Among the Top Dozen universal biomarkers (Table 2A) was
HTR2A, which was increased in expression and is targeted by most
modern antipsychotics, and ARRB1, which was decreased in
expression and is downstream of HTR2A in the signaling cascade,
and also interacts with GSK3B,25 which was decreased in
expression as well (Supplementary Figure S3). The combination
of these expression effects may provide for excessive/unbridled
signaling26 as a key pathological step in suicidality. For male
bipolars, similar STRING analysis revealed a network centered on
PTK2 (Supplementary Figure S4).
Finally, a post-hoc convergent functional evidence score of the
totality of evidence in these series of studies, including testing for
predictive ability, evidence for biological predisposition/involve-
ment in psychiatric disorders, and for being potential drug targets,
identiﬁes APOE and IL6 as the top overall biomarkers of interest,
pointing to stress, inﬂammation and accelerated aging (Figure 9
and Supplementary Table S7). It is unclear at this point whether
they are just markers of that co-occurring pathology or are direct
drivers of suicide as well.
Overall, we believe this work is a major step forward towards
understanding, diagnosing and treating suicidality. Suicide occurs
maladaptively in the face of negative life events, with the indivi-
dual who commits suicide being vulnerable due to a psychiatric
illness and addictions, misperceiving circumstances and/or over-
reacting in an impulsive manner. Related to that, suicide can be an
attempt to assuage perceived guilt or an attempt to harm
(through social opprobrium or guilt) the individual(s) perceived to
be the source of the suffering and lack of success of the suicidal
person. Conversely, a well-balanced and functioning mind is
protective. To predict behaviors, it may be important to provide
context to the biomarkers, as to how the person feels (SASS) and
who the person is (CFI-S) (Figure 5a). That is why the combined
UP-Suicide predictor is robust across all subjects, in subtypes and
personalized by gender and diagnosis, with AUCs over 90%
(Figure 6). We hope that our risk assessment tools may become
self-cancelling predictions once tested and deployed in the
general population, as they can lead to precision prevention with
early targeted interventions: biological, psychological and social.
Indeed, beyond biological markers and drug treatments, SASS can
help identify different subtypes and in different individuals
different CFI-S items are positive, providing avenues for tailored
and targeted (psycho)therapeutic interventions. Culture may have
a particularly important role (Figure 5a). Negative behaviors in the
past, negative examples from the environment and negative
cultural values can lead to a downward spiral of failure. Reversing
negative cultural inﬂuences on behaviors involves coming to
terms with or forgetting the past, starting to accumulate positive
precedents, changing the environment (or moving to a different
environment) and gravitating to/adopting a different set of
cultural values. Given that one person dies from suicide every
40 seconds worldwide, the importance and urgency of efforts
such as ours cannot be overstated.27 We demonstrate how this
ﬁeld can develop precision, move towards personalization, and
have tools to pre-empt suicide acutely, as well as prevent suicide
in the long term. We envision the participation of individuals at
risk in such efforts initially, followed by the pervasive deployment
of the tools in society at large in the long term. It has not escaped
our attention that, if our ‘life switch’ hypothesis between suicide
and longevity is correct,22 the possibility exists to transform a
negative into a positive.
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